Pennsylvania Firm Handing Out $5,000 per Person To Settle Lawsuit Over Data Breach That Exposed Social Security Numbers of at Least 1,400,000 People
A US pharmaceutical giant has agreed to compensate those who were impacted by a major 2024 data breach.
According to the newly updated settlement portal, Cencora (COR) will provide up to $5,000 to those impacted by a cybersecurity attack that reportedly impacted more than one million people.
A class action lawsuit was filed against Cencora after the company disclosed in February 2024 that hackers gained access to its systems and stole personal information.
“In a data breach notification letter dated December 12th, 2024, Cencora announced that World Courier Group and certain of its subsidiaries experienced a data breach that involved the personal information of current and former employees, including name, address, date of birth and Social Security number…
Cencora has not yet publicly confirmed the total number of individuals, pharmaceutical company partners, or other affiliated divisions or companies that were affected by its data breach. Public reports indicate, however, that the Data Breach resulted in the exfiltration of sensitive private information for at least 1.4 million individuals, relating to at least 27 partner pharmaceutical and biotechnology companies as well as other entities related to Cencora.”
Those who suffered losses as a result of the data breach can submit claims and documented losses for “up to $5,000 per person, subject to a cap of $5,000,000 for all documented loss payments.”
Pennsylvania-based Cencora says it generates more than $290 billion in annual revenue and has 51,000 employees.
Generated Image: Midjourney
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
ALGS drops 12.49% over 7 days amid optimism for HBV and MASH treatments
- Aligos Therapeutics (ALGS) saw a 12.49% 7-day stock decline despite positive HBV/MASH trial data. - Pevifoscorvir showed superior HBV DNA suppression and safety, with Phase II trials ongoing for 2026-2027 data. - ALG-009 demonstrated metabolic benefits for MASH, positioning Aligos as a key player in liver disease innovation. - Recent 23,600-share equity grants to new hires aim to strengthen R&D capabilities and operational growth.

The COAI Token Fraud: An Urgent Warning for Cryptocurrency Investors
- COAI token's 88% collapse in 2025 exposed DeFi vulnerabilities, driven by C3.ai leadership turmoil, $116.8M losses, and a class-action lawsuit. - Regulatory ambiguity (CLARITY Act) and technical flaws like Balancer's $116M exploit highlight systemic risks in decentralized finance. - Global DeFi exploits cost $2B+ in 2025, with Singapore reporting doubled fraud claims involving credential theft and impersonation. - Experts urge rigorous due diligence: audit smart contracts, analyze tokenomics, verify team

Cboe Introduces Nation’s First Regulated 10-Year Crypto Futures to Address Institutional Needs
- Cboe launches first U.S.-regulated 10-year Bitcoin/Ether Continuous Futures (PBT/PET) on Dec 15, 2025, offering institutional investors long-term crypto exposure without offshore reliance. - Products feature daily cash adjustments to spot prices, eliminating rollovers, and are centrally cleared via CFTC-regulated Cboe Clear U.S., enabling cross-margining with existing FBT/FET futures. - 23×5 trading schedule and Funding Amount mechanism align with market conditions, addressing operational friction while
PEPE Consolidates Near $0.055 as Support and Resistance Levels Shape a Tight Trading Range

